183 related articles for article (PubMed ID: 20188102)
1. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.
Bouchaud G; Mortier E; Flamant M; Barbieux I; Plet A; Galmiche JP; Jacques Y; Bourreille A
Gastroenterology; 2010 Jun; 138(7):2378-87. PubMed ID: 20188102
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.
Perrier C; Arijs I; Staelens D; Breynaert C; Cleynen I; Covens K; Ferrante M; Van Assche G; Vermeire S; de Hertogh G; Schuit F; Rutgeerts P; Ceuppens JL
Immunology; 2013 Jan; 138(1):47-56. PubMed ID: 23039249
[TBL] [Abstract][Full Text] [Related]
3. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
4. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer.
Badoual C; Bouchaud G; Agueznay Nel H; Mortier E; Hans S; Gey A; Fernani F; Peyrard S; -Puig PL; Bruneval P; Sastre X; Plet A; Garrigue-Antar L; Quintin-Colonna F; Fridman WH; Brasnu D; Jacques Y; Tartour E
Cancer Res; 2008 May; 68(10):3907-14. PubMed ID: 18483276
[TBL] [Abstract][Full Text] [Related]
5. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease.
Dideberg V; Théâtre E; Farnir F; Vermeire S; Rutgeerts P; De Vos M; Belaiche J; Franchimont D; Van Gossum A; Louis E; Bours V
Pharmacogenet Genomics; 2006 Oct; 16(10):727-34. PubMed ID: 17001292
[TBL] [Abstract][Full Text] [Related]
6. Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17).
Budagian V; Bulanova E; Orinska Z; Ludwig A; Rose-John S; Saftig P; Borden EC; Bulfone-Paus S
J Biol Chem; 2004 Sep; 279(39):40368-75. PubMed ID: 15215246
[TBL] [Abstract][Full Text] [Related]
7. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
8. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
Ogawa K; Matsumoto T; Esaki M; Torisu T; Iida M
J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
[TBL] [Abstract][Full Text] [Related]
9. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.
Di Sabatino A; Pender SL; Jackson CL; Prothero JD; Gordon JN; Picariello L; Rovedatti L; Docena G; Monteleone G; Rampton DS; Tonelli F; Corazza GR; MacDonald TT
Gastroenterology; 2007 Jul; 133(1):137-49. PubMed ID: 17631138
[TBL] [Abstract][Full Text] [Related]
10. The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-α therapy.
Sandahl TD; Kelsen J; Dige A; Dahlerup JF; Agnholt J; Hvas CL; Thiel S
J Crohns Colitis; 2014 Jun; 8(6):521-8. PubMed ID: 24291022
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
12. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease.
Gao Q; Meijer MJ; Schlüter UG; van Hogezand RA; van der Zon JM; van den Berg M; van Duijn W; Lamers CB; Verspaget HW
Inflamm Bowel Dis; 2007 Jun; 13(6):693-702. PubMed ID: 17243139
[TBL] [Abstract][Full Text] [Related]
13. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
14. Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn's disease.
Detková Z; Kupcová V; Príkazská M; Turecký L; Weissová S; Jahnová E
Physiol Res; 2003; 52(1):95-100. PubMed ID: 12625813
[TBL] [Abstract][Full Text] [Related]
15. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
[TBL] [Abstract][Full Text] [Related]
16. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
[TBL] [Abstract][Full Text] [Related]
17. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
18. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease.
Song L; Hanlon DW; Chang L; Provuncher GK; Kan CW; Campbell TG; Fournier DR; Ferrell EP; Rivnak AJ; Pink BA; Minnehan KA; Patel PP; Wilson DH; Till MA; Faubion WA; Duffy DC
J Immunol Methods; 2011 Sep; 372(1-2):177-86. PubMed ID: 21821036
[TBL] [Abstract][Full Text] [Related]
19. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
